Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A6 | P11509 | 1/20 | 0.39 |
| ▸ | IDO1 | P14902 | 1/20 | 0.38 |
| ▸ | CCR1 | P32246 | 1/20 | 0.36 |
| ▸ | CCR5 | P51681 | 1/20 | 0.36 |
| ▸ | CCR8 | P51685 | 1/20 | 0.36 |
| ▸ | F2 | P00734 | 1/20 | 0.36 |
| ▸ | F10 | P00742 | 1/20 | 0.36 |
| ▸ | F7 | P08709 | 1/20 | 0.36 |
| ▸ | F3 | P13726 | 1/20 | 0.36 |
| ▸ | TGFBR1 | P36897 | 5/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | GRM5 | P41594 | 2/20 | 0.35 |
| ▸ | ACP1 | P24666 | 1/20 | 0.35 |
| ▸ | METAP1 | P53582 | 2/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2321937 | 0.90 | MAPK1 (0.40) | IDO1F2F10F7F3 | |
| SCHEMBL12440325 | 0.88 | PDGFRB (0.40) | IDO1F2F10F7F3 | |
| SCHEMBL12440326 | 0.88 | ABCG2 (0.40) | CYP2A6IDO1TGFBR1ACP1KDM4E | |
| SCHEMBL13968337 | 0.87 | CYP2A6 (0.41) | CYP2A6IDO1TGFBR1ABCG2 | |
| SCHEMBL13834933 | 0.86 | IDO1 (0.36) | IDO1F2F10F7F3 | |
| SCHEMBL13834954 | 0.86 | TGFBR1 (0.38) | IDO1TGFBR1ABCG2PRKD3PRKD1 | |
| SCHEMBL2324957 | 0.85 | IDO1 (0.38) | IDO1F2F10F7F3 | |
| SCHEMBL12441208 | 0.85 | HSP90AA1 (0.43) | L3MBTL1KDM4ENPC1RAB9ASMN1; SMN2 | |
| SCHEMBL12440270 | 0.85 | CYP11B1 (0.39) | IDO1TGFBR1KDM4EALDH1A1HPGD | |
| SCHEMBL12441217 | 0.85 | CNR1 (0.38) | IDO1TGFBR1CYP11B1CYP11B2ABCG2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2531500-B1 | HETARYL-[1,8]NAPHTHYRIDINE DERIVATIVES | MERCK PATENT GMBH (DE) | 2018-01-24 | — | — | EP | disclosed |
| EP-2531500-B1 | HETARYL-[1,8]NAPHTHYRIDINE DERIVATIVES | MERCK PATENT GMBH (DE) | 2018-01-24 | — | — | EP | disclosed |
| US-8912216-B2 | Hetaryl-[1,8]naphthyridine derivatives | MERCK PATENT GMBH (DE) | 2014-12-16 | — | — | US | disclosed |
| US-8912216-B2 | Hetaryl-[1,8]naphthyridine derivatives | MERCK PATENT GMBH (DE) | 2014-12-16 | — | — | US | disclosed |
| US-8912216-B2 | Hetaryl-[1,8]naphthyridine derivatives | MERCK PATENT GMBH (DE) | 2014-12-16 | — | — | US | disclosed |
| US-20140038960-A1 | Hetaryl-[1,8]naphthyridine derivatives | MERCK PATENT GMBH (DE) | 2014-02-06 | — | — | US | disclosed |
| US-20140038960-A1 | Hetaryl-[1,8]naphthyridine derivatives | MERCK PATENT GMBH (DE) | 2014-02-06 | — | — | US | disclosed |
| US-20140038960-A1 | Hetaryl-[1,8]naphthyridine derivatives | MERCK PATENT GMBH (DE) | 2014-02-06 | — | — | US | disclosed |
| US-8614226-B2 | Hetaryl-[1,8]naphthyridine derivatives | MERCK PATENT GMBH (DE) | 2013-12-24 | — | — | US | disclosed |
| US-20120295902-A1 | Hetaryl-[1,8]naphthyridine derivatives | MERCK PATENT GMBH (DE) | 2012-11-22 | — | — | US | disclosed |
| US-20120295902-A1 | Hetaryl-[1,8]naphthyridine derivatives | MERCK PATENT GMBH (DE) | 2012-11-22 | — | — | US | disclosed |
| US-20120295902-A1 | Hetaryl-[1,8]naphthyridine derivatives | MERCK PATENT GMBH (DE) | 2012-11-22 | — | — | US | disclosed |
| WO-2011095196-A1 | HETARYL-[1,8]NAPHTHYRIDINE DERIVATIVES | MERCK PATENT GMBH (DE) | 2011-08-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140038960-A1 | Hetaryl-[1,8]naphthyridine derivatives | ATP5F1A, ATP5ME, ATP5F1D | CYP2A6 456/4885IDO1 1404/4885CCR1 4821/4885 |
| US-20120295902-A1 | Hetaryl-[1,8]naphthyridine derivatives | ATP5F1A, ATP5ME, ATP5F1D | CYP2A6 456/4885IDO1 1404/4885CCR1 4821/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.